
Gary Curhan, MD, Chief Medical Officer, OM1, Brand Insights Contributor
Advertisement
Articles by Gary Curhan, MD, Chief Medical Officer, OM1, Brand Insights Contributor

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
4
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
5